Effects of Tolvasttan Combined with Fluvastatin on Vascular Endothelial Function and Serum Nexilin and CASP3 Levels in Patients with Chronic Heart Failure
Objective To investigate the effects of tolvasttan combined with fluvastatin on vascular endothelial function and serum levels of Nexilin and cysteine aspartic protease-3(CASP3)in patients with chronic heart failure(CHF).Methods The data of 86 patients with CHF were retrospectively analyzed,and they were divided into control group(receiving fluvastatin treatment)and observation group(receiving torvasttan+fluvastatin treatment)according to different treatment plans,with 43 cases in each group.The clinical efficacy,cardiac function[stroke volume(SV),myocardial energy expenditure(MEE),left atrial diameter(LAD),left ventricular ejection fraction(LVEF)],vascular endothelial function[nitric oxide(NO),calcitonin gene-related peptide(CGRP),endothelin-1(ET-1)],serum Nexilin,CASP3 and adverse reactions were compared between the two groups.Results The total effective rate of the study group(90.70%)was higher than that of the control group(72.09%)(P<0.05).Compared with before treatment,MEE and LAD were decreased in both groups,SV and LVEF were increased,and the study group was more significant(P<0.05).Compared with before treatment,NO and CGRP were significantly increased and ET-1 was significantly decreased in the group after treatment(P<0.05).Compared with before treatment,the reduction of Nexilin and CASP3 in the study group after treatment was greater than that in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Torvasttan combined with fluvastatin is effective in the treatment of CHF,it can down-regulate the expression of Nexilin and CASP3,improve vascular endothelial function,enhance cardiac function,and has high safety.
万方数据
维普
